|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PBK |
Gene summary for PBK |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PBK | Gene ID | 55872 |
| Gene name | PDZ binding kinase | |
| Gene Alias | CT84 | |
| Cytomap | 8p21.1 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | Q96KB5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55872 | PBK | LZE2T | Human | Esophagus | ESCC | 9.54e-06 | 5.13e-01 | 0.082 |
| 55872 | PBK | P2T-E | Human | Esophagus | ESCC | 9.35e-10 | 3.58e-01 | 0.1177 |
| 55872 | PBK | P4T-E | Human | Esophagus | ESCC | 1.40e-18 | 6.33e-01 | 0.1323 |
| 55872 | PBK | P5T-E | Human | Esophagus | ESCC | 9.44e-07 | 2.18e-01 | 0.1327 |
| 55872 | PBK | P9T-E | Human | Esophagus | ESCC | 2.30e-02 | 1.14e-01 | 0.1131 |
| 55872 | PBK | P10T-E | Human | Esophagus | ESCC | 4.44e-08 | 3.11e-01 | 0.116 |
| 55872 | PBK | P15T-E | Human | Esophagus | ESCC | 3.26e-02 | 1.22e-01 | 0.1149 |
| 55872 | PBK | P16T-E | Human | Esophagus | ESCC | 3.75e-03 | 1.32e-01 | 0.1153 |
| 55872 | PBK | P17T-E | Human | Esophagus | ESCC | 4.79e-04 | 2.68e-01 | 0.1278 |
| 55872 | PBK | P20T-E | Human | Esophagus | ESCC | 1.51e-02 | 1.51e-01 | 0.1124 |
| 55872 | PBK | P21T-E | Human | Esophagus | ESCC | 1.76e-12 | 3.40e-01 | 0.1617 |
| 55872 | PBK | P22T-E | Human | Esophagus | ESCC | 1.66e-02 | 1.47e-01 | 0.1236 |
| 55872 | PBK | P24T-E | Human | Esophagus | ESCC | 2.06e-08 | 2.87e-01 | 0.1287 |
| 55872 | PBK | P26T-E | Human | Esophagus | ESCC | 3.75e-03 | 1.24e-01 | 0.1276 |
| 55872 | PBK | P28T-E | Human | Esophagus | ESCC | 9.53e-09 | 2.30e-01 | 0.1149 |
| 55872 | PBK | P30T-E | Human | Esophagus | ESCC | 2.13e-03 | 3.18e-01 | 0.137 |
| 55872 | PBK | P31T-E | Human | Esophagus | ESCC | 2.05e-07 | 1.87e-01 | 0.1251 |
| 55872 | PBK | P32T-E | Human | Esophagus | ESCC | 7.31e-14 | 4.13e-01 | 0.1666 |
| 55872 | PBK | P36T-E | Human | Esophagus | ESCC | 2.11e-03 | 3.45e-01 | 0.1187 |
| 55872 | PBK | P37T-E | Human | Esophagus | ESCC | 1.09e-08 | 2.78e-01 | 0.1371 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:005140316 | Oral cavity | OSCC | stress-activated MAPK cascade | 134/7305 | 239/18723 | 6.02e-08 | 1.09e-06 | 134 |
| GO:004340917 | Oral cavity | OSCC | negative regulation of MAPK cascade | 105/7305 | 180/18723 | 1.10e-07 | 1.87e-06 | 105 |
| GO:007030210 | Oral cavity | OSCC | regulation of stress-activated protein kinase signaling cascade | 111/7305 | 195/18723 | 2.82e-07 | 4.34e-06 | 111 |
| GO:003287210 | Oral cavity | OSCC | regulation of stress-activated MAPK cascade | 108/7305 | 192/18723 | 8.97e-07 | 1.22e-05 | 108 |
| GO:004586120 | Oral cavity | OSCC | negative regulation of proteolysis | 181/7305 | 351/18723 | 1.01e-06 | 1.37e-05 | 181 |
| GO:200005919 | Oral cavity | OSCC | negative regulation of ubiquitin-dependent protein catabolic process | 35/7305 | 48/18723 | 1.93e-06 | 2.47e-05 | 35 |
| GO:190336317 | Oral cavity | OSCC | negative regulation of cellular protein catabolic process | 49/7305 | 75/18723 | 3.49e-06 | 4.15e-05 | 49 |
| GO:00324359 | Oral cavity | OSCC | negative regulation of proteasomal ubiquitin-dependent protein catabolic process | 26/7305 | 35/18723 | 2.40e-05 | 2.26e-04 | 26 |
| GO:190305117 | Oral cavity | OSCC | negative regulation of proteolysis involved in cellular protein catabolic process | 41/7305 | 64/18723 | 4.31e-05 | 3.71e-04 | 41 |
| GO:003287310 | Oral cavity | OSCC | negative regulation of stress-activated MAPK cascade | 34/7305 | 51/18723 | 5.83e-05 | 4.80e-04 | 34 |
| GO:007030310 | Oral cavity | OSCC | negative regulation of stress-activated protein kinase signaling cascade | 34/7305 | 51/18723 | 5.83e-05 | 4.80e-04 | 34 |
| GO:00094164 | Oral cavity | OSCC | response to light stimulus | 159/7305 | 320/18723 | 5.98e-05 | 4.92e-04 | 159 |
| GO:00182123 | Oral cavity | OSCC | peptidyl-tyrosine modification | 180/7305 | 378/18723 | 3.63e-04 | 2.22e-03 | 180 |
| GO:19017998 | Oral cavity | OSCC | negative regulation of proteasomal protein catabolic process | 31/7305 | 49/18723 | 5.04e-04 | 2.95e-03 | 31 |
| GO:0071482 | Oral cavity | OSCC | cellular response to light stimulus | 66/7305 | 123/18723 | 6.74e-04 | 3.77e-03 | 66 |
| GO:00181083 | Oral cavity | OSCC | peptidyl-tyrosine phosphorylation | 177/7305 | 375/18723 | 6.86e-04 | 3.83e-03 | 177 |
| GO:001049828 | Skin | cSCC | proteasomal protein catabolic process | 243/4864 | 490/18723 | 7.85e-30 | 4.10e-27 | 243 |
| GO:004217629 | Skin | cSCC | regulation of protein catabolic process | 198/4864 | 391/18723 | 6.03e-26 | 1.89e-23 | 198 |
| GO:004316128 | Skin | cSCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 205/4864 | 412/18723 | 1.46e-25 | 4.16e-23 | 205 |
| GO:190336229 | Skin | cSCC | regulation of cellular protein catabolic process | 139/4864 | 255/18723 | 2.06e-22 | 4.17e-20 | 139 |
| Page: 1 2 3 4 5 6 7 8 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PBK | SNV | Missense_Mutation | c.640N>A | p.Glu214Lys | p.E214K | Q96KB5 | protein_coding | tolerated(0.31) | benign(0.006) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR | |
| PBK | SNV | Missense_Mutation | novel | c.118N>C | p.Phe40Leu | p.F40L | Q96KB5 | protein_coding | tolerated(0.13) | benign(0.005) | TCGA-E9-A54Y-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| PBK | insertion | Frame_Shift_Ins | novel | c.50_51insA | p.Lys18GlufsTer50 | p.K18Efs*50 | Q96KB5 | protein_coding | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | ||
| PBK | SNV | Missense_Mutation | c.224G>A | p.Arg75Gln | p.R75Q | Q96KB5 | protein_coding | tolerated(1) | benign(0.003) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| PBK | SNV | Missense_Mutation | c.35A>G | p.Lys12Arg | p.K12R | Q96KB5 | protein_coding | tolerated(0.46) | benign(0.001) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| PBK | SNV | Missense_Mutation | c.172N>A | p.His58Asn | p.H58N | Q96KB5 | protein_coding | tolerated(0.07) | benign(0.139) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
| PBK | SNV | Missense_Mutation | novel | c.316N>A | p.Ala106Thr | p.A106T | Q96KB5 | protein_coding | tolerated(0.1) | benign(0.088) | TCGA-CK-5913-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PBK | SNV | Missense_Mutation | c.265N>G | p.Leu89Val | p.L89V | Q96KB5 | protein_coding | deleterious(0.01) | possibly_damaging(0.651) | TCGA-AF-3911-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fu | PD | |
| PBK | SNV | Missense_Mutation | novel | c.725T>G | p.Phe242Cys | p.F242C | Q96KB5 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PBK | SNV | Missense_Mutation | novel | c.176N>T | p.Ser59Phe | p.S59F | Q96KB5 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 55872 | PBK | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, DRUG RESISTANCE, TYROSINE KINASE, ENZYME | LINIFANIB | LINIFANIB | ||
| 55872 | PBK | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, DRUG RESISTANCE, TYROSINE KINASE, ENZYME | BAY-613606 | CHEMBL541400 | ||
| 55872 | PBK | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, DRUG RESISTANCE, TYROSINE KINASE, ENZYME | inhibitor | 223366144 | ||
| 55872 | PBK | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, DRUG RESISTANCE, TYROSINE KINASE, ENZYME | SP-600125 | SP-600125 | ||
| 55872 | PBK | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, DRUG RESISTANCE, TYROSINE KINASE, ENZYME | GEFITINIB | GEFITINIB | 26745678 | |
| 55872 | PBK | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, DRUG RESISTANCE, TYROSINE KINASE, ENZYME | PHA-767491 | CHEMBL225519 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |